LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

LLY

1,061.04

+3.27%↑

JNJ

214.42

+1.41%↑

ABBV

227.63

+1.87%↑

UNH

341.44

+0.01%↑

AZN

91.59

+2%↑

Strona główna・Stock List・Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics Inc

Closed

SectorHealthcare

28.98 0.1

Buy Sell

Overview

Share price change

24h

Current

Min

28.37

Max

29.46

Key metrics
By Trading Economics
Income	23M 7.4M
Sales	18M 99M
EPS	0.06
Profit margin	7.468
Employees	342
EBITDA	23M 11M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+1.65% upside

Market Stats
By TradingEconomics
Market Cap	1.4B 3.8B
Previous open	28.88
Previous close	28.98

News Sentiment

By Acuity

50%

165 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

12.42 / 14.93 Support & Resistance

Arcutis Biotherapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 gru 2025, 17:39 UTC

Major Market Movers

Vanda Pharmaceuticals Rises on FDA Biologics License Application

15 gru 2025, 23:44 UTC

Market Talk

Gold Steady Ahead of U.S. Employment Report -- Market Talk

15 gru 2025, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

15 gru 2025, 23:38 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

15 gru 2025, 22:19 UTC

Market Talk

Clean-Energy Project Developers Benefit From 'Deep Buyer Universe' -- Market Talk

15 gru 2025, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

15 gru 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Comcast Spinoff Versant Debuts at Modest Valuation, a Signal for a Warner Bros. Sale -- Barrons.com

15 gru 2025, 21:32 UTC

Acquisitions, Mergers, Takeovers

Comcast Spinoff Versant Debuts at Modest Valuation, Puts Warner Bros. Discovery in Focus -- Barrons.com

15 gru 2025, 21:28 UTC

Acquisitions, Mergers, Takeovers

iRobot Files for Bankruptcy After Amazon Was Forced to Scrap Its Deal to Buy the Roomba Maker -- Barrons.com

15 gru 2025, 21:26 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Completes Acquisition of Foley Products for $1.84B >CMC

15 gru 2025, 21:23 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Reserves Right to Make Further Proposal If Circumstances Change

15 gru 2025, 21:23 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Does Not Intend to Submit Revised Takeover Proposal For Predictive

15 gru 2025, 21:23 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Notes Predictive Shares Trade at Discount to Value Implied By Perseus Proposal

15 gru 2025, 21:22 UTC

Acquisitions, Mergers, Takeovers

Perseus Mining: Believes Revised Robex Merger Inferior to Its Own Takeover Proposal

15 gru 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Completes Acquisition Of Foley Products Company >CMC

15 gru 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

ServiceNow Completes Acquisition Of Moveworks >NOW

15 gru 2025, 21:00 UTC

Acquisitions, Mergers, Takeovers

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 gru 2025, 20:57 UTC

Acquisitions, Mergers, Takeovers

Comcast Spinoff Versant Debuts at Low Valuation; Could Figure in Warner Bros. Discovery Takeover Battle -- Barrons.com

15 gru 2025, 20:36 UTC

Market Talk

Oil Futures Fall Further on Oversupply Concerns -- Market Talk

15 gru 2025, 20:31 UTC

Market Talk

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

15 gru 2025, 20:27 UTC

Market Talk

Acquisitions, Mergers, Takeovers

ServiceNow's Acquisition Streak Could Cause Investor Angst -- Market Talk

15 gru 2025, 20:15 UTC

Market Talk

El Buen Fin Helps Lift Mexican November Retail Sales -- Market Talk

15 gru 2025, 19:22 UTC

Market Talk

Gold and Silver Gain to Start Week -- Market Talk

15 gru 2025, 18:37 UTC

Market Talk

Oil Futures Extend Losses On Oversupply Worries -- Market Talk

15 gru 2025, 18:29 UTC

Market Talk

ServiceNow Seen Facing Pressure if Government Budgets Decline -- Market Talk

15 gru 2025, 17:58 UTC

Market Talk

Canada Housing Market In Search Of a Bottom -- Market Talk

15 gru 2025, 17:36 UTC

Market Talk

Canada Data Signal Underlying Price Pressures Persist -- Market Talk

15 gru 2025, 17:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 gru 2025, 17:36 UTC

Earnings

Texas Instruments Stock Slips. It Caught a Rare Downgrade From Goldman Sachs. -- Barrons.com

15 gru 2025, 17:30 UTC

Acquisitions, Mergers, Takeovers

Cinemark Stock Could Fall Even More If Netflix Buys Warner Bros., Analyst Says -- Barrons.com

Peer Comparison

Price change

Arcutis Biotherapeutics Inc Forecast

Price Target

By TipRanks

1.65% upside

12 Months Forecast

Average 29.5 USD 1.65%

High 37 USD

Low 21 USD

Based on 6 Wall Street analysts offering 12 month price targets forArcutis Biotherapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Based on 6 analysts giving stock ratings to Arcutis Biotherapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

12.42 / 14.93Support & Resistance

Recent bearish events outweigh bullish events.

There is one bullish event.

Sentiment

By Acuity

165 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.